Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
Aura Biosciences (AURA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Aura Biosciences's actual EPS was -$0.55, missing the estimate of -$0.50 per share, resulting in a -9.78% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
